INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30201, 6627, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30202, 12220, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30203, 12222, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30204, 15848, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30205, 19879, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30206, 19880, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30207, 21019, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30208, 21106, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30209, 21107, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30210, 21108, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30211, 21109, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30212, 29139, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30213, 29141, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30214, 29182, 'Verapamil', 'Heart Failure', 'The use of verapamil is contraindicated in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, verapamil should not be given to patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened.  Verapamil has a negative inotropic effect, which in most patients is compensated by a simultaneous reduction in afterload (i.e. decreased systemic vascular resistance) without a net impairment of ventricular performance.  However, congestive heart failure or pulmonary edema have developed in approximately 2% of patients treated with verapamil.  Mild symptoms of cardiac failure should be under control, if possible, prior to initiating verapamil therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30215, 2066, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30216, 6622, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30217, 6625, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30218, 6627, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30219, 12220, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30220, 12222, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30221, 15848, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30222, 19879, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30223, 19880, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30224, 21019, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30225, 21106, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30226, 21107, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30227, 21108, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30228, 21109, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30229, 29139, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30230, 29141, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30231, 29182, 'Verapamil', 'Cardiomyopathy, Hypertrophic', 'The use of verapamil in patients with hypertrophic cardiomyopathy, or idiopathic hypertrophic subaortic stenosis, has been associated with serious side effects such as pulmonary edema, severe hypotension, sinus bradycardia, AV block, sinus arrest, and death.  However, a causal relationship has not been established.  Therapy with verapamil should be administered cautiously in patients with hypertrophic cardiomyopathy.  Dosage reduction or drug discontinuation may be required if severe adverse effects occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30232, 2066, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30233, 6622, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30234, 6625, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30235, 6627, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30236, 12220, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30237, 12222, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30238, 15848, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30239, 19879, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30240, 19880, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30241, 21019, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30242, 21106, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30243, 21107, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30244, 21108, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30245, 21109, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30246, 29139, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30247, 29141, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30248, 29182, 'Verapamil', 'Neuromuscular Junction Diseases', 'Verapamil has been reported to decrease neuromuscular transmission in patients with Duchenne''s muscular dystrophy and to prolong recovery from the neuromuscular blocking agent, vecuronium.  Therapy with verapamil should be administered cautiously in patients with attenuated neuromuscular transmission or myopathy, since these conditions may be exacerbated.  A reduced dosage may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30249, 2066, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30250, 6622, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30251, 6625, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30252, 6627, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30253, 12220, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30254, 12222, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30255, 15848, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30256, 19879, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30257, 19880, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30258, 21019, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30259, 21106, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30260, 21107, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30261, 21108, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30262, 21109, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30263, 29139, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30264, 29141, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30265, 29182, 'Verapamil', 'Kidney Diseases', 'Approximately 70% of an administered dose of verapamil is excreted as metabolites in the urine.  The primary metabolite, norverapamil, has about 20% the cardiovascular activity and can reach steady-state plasma concentrations approaching those of the parent drug.  Patients with impaired renal function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with verapamil should be administered cautiously in such patients, with appropriate monitoring for excessive pharmacologic effects (e.g., abnormal prolongation of PR interval) and the dosage adjusted accordingly as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30266, 2066, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30267, 6622, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30268, 6625, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30269, 6627, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30270, 12220, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30271, 12222, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30272, 15848, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30273, 19879, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30274, 19880, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30275, 21019, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30276, 21106, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30277, 21107, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30278, 21108, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30279, 21109, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30280, 29139, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30281, 29141, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30282, 29182, 'Verapamil', 'Intestinal Obstruction', 'The controlled-onset, extended-release formulation of verapamil (Covera-HS) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-onset, extended-release formulation of verapamil should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30283, 2471, 'Varenicline', 'Mental Disorders', 'Serious neuropsychiatric events including, but not limited to, depression, suicidal ideation, suicide attempt, and completed suicide have been reported in patients taking varenicline.  Caution is recommended and patients should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30284, 16219, 'Varenicline', 'Mental Disorders', 'Serious neuropsychiatric events including, but not limited to, depression, suicidal ideation, suicide attempt, and completed suicide have been reported in patients taking varenicline.  Caution is recommended and patients should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30285, 2471, 'Varenicline', 'Alcoholism', 'Varenicline can enhance the response to alcohol and patients may experience increased intoxicating effects.  In patients who may use alcohol excessively, it should be kept in mind that the potentiation may increase the danger associated with the use of alcohol.  Advise patients to reduce the amount of alcohol they consume and to use caution driving or operating machinery or engaging in other potentially hazardous activities while taking varenicline until they know how this agent may affect them.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30286, 16219, 'Varenicline', 'Alcoholism', 'Varenicline can enhance the response to alcohol and patients may experience increased intoxicating effects.  In patients who may use alcohol excessively, it should be kept in mind that the potentiation may increase the danger associated with the use of alcohol.  Advise patients to reduce the amount of alcohol they consume and to use caution driving or operating machinery or engaging in other potentially hazardous activities while taking varenicline until they know how this agent may affect them.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30287, 2471, 'Varenicline', 'Cardiovascular Diseases', 'There have been reports of cardiovascular events, including ischemic and hemorrhagic events in patients taking varenicline.  Caution is recommended when prescribing this agent.  Patients should be monitored for signs of new or worsening symptoms of cardiovascular disease and appropriate therapy should be instituted according to medical guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30288, 16219, 'Varenicline', 'Cardiovascular Diseases', 'There have been reports of cardiovascular events, including ischemic and hemorrhagic events in patients taking varenicline.  Caution is recommended when prescribing this agent.  Patients should be monitored for signs of new or worsening symptoms of cardiovascular disease and appropriate therapy should be instituted according to medical guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30289, 2471, 'Varenicline', 'Kidney Diseases', 'Varenicline is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Dose reduction is not required in patients with mild to moderate renal impairment.  Dosage adjustment is needed in patients with severe renal impairment, and those with end-stage renal disease undergoing hemodialysis.  Varenicline has been shown to be dialyzed in patients with end-stage renal disease.  Monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30290, 16219, 'Varenicline', 'Kidney Diseases', 'Varenicline is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Dose reduction is not required in patients with mild to moderate renal impairment.  Dosage adjustment is needed in patients with severe renal impairment, and those with end-stage renal disease undergoing hemodialysis.  Varenicline has been shown to be dialyzed in patients with end-stage renal disease.  Monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30291, 2471, 'Varenicline', 'Seizures', 'Seizures have been reported with varenicline therapy.  Therapy with this drug should be administered with caution and monitoring is recommended in patients with a history of seizures or other factors that can lower the seizure threshold.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30292, 16219, 'Varenicline', 'Seizures', 'Seizures have been reported with varenicline therapy.  Therapy with this drug should be administered with caution and monitoring is recommended in patients with a history of seizures or other factors that can lower the seizure threshold.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30293, 209, 'Valsartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30294, 2084, 'Valsartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30295, 3718, 'Valsartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30296, 3739, 'Valsartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30297, 3741, 'Valsartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30298, 11177, 'Valsartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30299, 11178, 'Valsartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30300, 11179, 'Valsartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', '', 'DDInter', 0);
